LDN Social Media
Get connected with us on social networks
Reza G. Marangaloo et al., German Journal of Veterinary Research, 20th February 2024
https://gmpc-akademie.de/articles/1709702482_2024_4_1_0070_GJVR_Marangaloo.pdf
Abstract
Naltrexone was first developed in 1963 as an opioid antagonist for therapeutic use in opioid-dependent individuals (alcohol, narcotics, and tobacco) with a 50 mg/day dose approved by the Food and Drug
Administration (FDA). In 1985, Dr. Bernard Bihari explained that when naltrexone is taken in very low doses (1-5 mg/day) before bedtime, it blocks opioid receptors for 2- 4 hours and leads to the release of
endorphins in the early morning hours, serving as an opioid agonist and immunomodulatory agent.
This extra endorphin secretion has been proven to enhance the immune system response in AIDS patients.
Endogenous opioids that affect cell development are referred to as opioid growth factor (OGF) and metenkephalin (ME). Low-dose-naltrexone (LDN) pharmacotherapeutically possesses immunomodulatory,
anticarcinogenic, antiviral, antibacterial, antiparasitic, and antifungal properties. LDN also increases the production and sensitivity of OGF, ME, and OGF receptor (OGFr) in the bloodstream, thereby
enhancing quality of life. Based on these pharmacotherapeutic properties, LDN application is believed to be effective in the treatment or prophylaxis of various infectious diseases in cats and dogs, particularly vasculitis-related diseases such as feline infectious peritonitis (FIP) and infectious canine hepatitis (ICH), hypothyroidism, gastrointestinal disorders, spondylosis, rheumatoid arthritis, autoimmune diseases, pneumonia, atopic and allergic dermatitis, pyodermas, resistant pyodermas, methicillin-resistant Staphylococcus aureus (MRSA) or various gastrointestinal disorders, alopecia, stubborn dermatomycosis, stubborn demodicosis, various geriatric and oncogenic diseases, and deep depressions or obsessivecompulsive disorders. Thus, this review aims to evaluate the pharmacotherapeutic properties of LDN
therapy usage and mechanisms of action in detail and assess the potential indications in cats and dogs based on these mechanisms.
Keywords: Immunomodulators, Therapy, Low-dose-naltrexone, LDN, Cats, Dogs